CGEM CIK: 1789972

Cullinan Therapeutics, Inc.

  • United States
  • Healthcare
  • Biotech
Metrics score locked — part of Premium
FY21
FY22
FY23
FY24
FY25
FY21 – FY25

Assets

(positive)
Change from FY21 to FY25
millions USD
FY21:
297
FY22:
474
FY23:
480
FY24:
415
FY25:
387
(positive)
Change from FY21 to FY25
millions USD
FY21:
141
FY22:
86.6
FY23:
3.99
FY24:
207
FY25:
61.6
Total assets
Change from FY21 to FY25
millions USD
FY21:
437
FY22:
561
FY23:
484
FY24:
622
FY25:
448

Liabilities & Equity

(negative)
Change from FY21 to FY25
millions USD
FY21:
11.7
FY22:
22.5
FY23:
28.1
FY24:
30.6
FY25:
37.7
(negative)
Change from FY21 to FY25
millions USD
FY21:
0.07
FY22:
3.59
FY23:
2.15
FY24:
0.85
FY25:
1.90
(positive)
Change from FY21 to FY25
millions USD
FY21:
425
FY22:
535
FY23:
454
FY24:
590
FY25:
409
Total liabilities & equity
Change from FY21 to FY25
millions USD
FY21:
437
FY22:
561
FY23:
484
FY24:
622
FY25:
448

All amounts in millions USD Data source:SEC EDGAR